AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Dyve Bioscience Announces Positive Results from Pilot Study in Gout Pain at European Crystal Network Workshop 2019

March 20, 2019

THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Mar 20, 2019--Dyve Bioscience, a biotech drug delivery company developing novel transdermal technologies for delivery of molecules through the skin, announced positive results from a human proof-of-concept pilot study of transdermal sodium bicarbonate for reducing pain associated with an acute gout flare.

An abstract of the results of the gout study was selected for oral presentation last week at the prestigious European Crystal Network 10 th workshop 2019 in Paris, and was presented by Lisa Misell, Ph.D., VP of Clinical and Medical Affairs for Dyve Bioscience. Findings of the randomized double-blinded placebo-controlled pilot study demonstrated the effectiveness of topical transdermal-delivery sodium bicarbonate for treating the pain associated with an acute gout flare.

“Our mission is to change the standard of care for people suffering from acute gout pain, by providing immediate relief through a safe transdermal technology,” said Dr. Misell. “We are pleased with the results of this study and the company is preparing to advance the treatment into the next phase of development.”

Principal investigators Smitha Reddy, M.D., Arthritis Care and Research Center, and Arthur Ray Mabaquiao, M.D., Cabrillo Center for Rheumatic Diseases, both in San Diego, evaluated outcomes of pain relief, days until resolution and improvement in range of motion. The study enrolled 24 men and women, aged 18 to 65, with history of gout. The active treatment patients received lotion containing sodium bicarbonate and menthol while the placebo group received lotion without those ingredients. Participants were told to report to clinic within 36 hours of flare onset; all were taking 0.6mg/d or were started on 0.6mg/d colchicine.

Patients in the study were directed to apply 10 mL of lotion every 4 hours, three applications a day, to the entire limb of the target joint (identified by investigator using questionnaire) and up to two other involved joints. Follow-up time points were 15 and 30 minutes, 1, 2, 4, 6, 8, 10, 12, and 14 days, with the data collected by phone.

“We are thrilled that a high percentage of patients had immediate pain relief, as early as 15 minutes after applying treatment,” said Dr. Reddy, Member of Dyve Bioscience’s Scientific Advisory Board and principal investigator. “This could prove to be a major advancement for those suffering from gout, given the current treatment options available, which can take days to provide relief.”

Gout afflicts approximately 2-4% of the US population (10M+) and can range as high as 10% in some countries. 1 However, the vast majority of treatments focus on chronic management, with very few that work within the first days following an acute attack. Of those options, some are associated with risks that make them unavailable to some patients.

1. Kuo CF, Grainge MJ, Zhang W, Doherty M. Global epidemiology of gout: prevalence, incidence and risk factors. Nat Rev Rheumatol. 2015 Nov;11(11):649-62.

About Dyve Biosciences

Dyve Biosciences is rapidly developing a strong pipeline across a broad range of therapeutic areas based around its proprietary Dyve skin penetration technology. The innovative approach enables therapy to be transported fast and deep through the skin, allowing rapid penetration into targeted tissue. This unique approach offers the promise of delivering therapeutic molecules to areas that could previously only be reached with a needle. At Dyve, the focus is on robust science, compelling data, and delivering positive patient outcomes. For more information please visit www.dyvebio.com

View source version on businesswire.com:https://www.businesswire.com/news/home/20190320005182/en/

CONTACT: Amy Phillips

Pascale

C: 412.327.9499

amy@pascalecommunications.com

KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA

INDUSTRY KEYWORD: STEM CELLS TECHNOLOGY SOFTWARE PRACTICE MANAGEMENT HEALTH BIOTECHNOLOGY CARDIOLOGY CLINICAL TRIALS FITNESS & NUTRITION HOSPITALS INFECTIOUS DISEASES MEDICAL DEVICES ONCOLOGY PHARMACEUTICAL OTHER HEALTH RESEARCH OTHER SCIENCE FDA SCIENCE

SOURCE: Dyve Biosciences

Copyright Business Wire 2019.

PUB: 03/20/2019 07:00 AM/DISC: 03/20/2019 07:00 AM

http://www.businesswire.com/news/home/20190320005182/en